Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]pyruvate

Science Translational Medicine

Volumn 5, Issue 198, 2013, Pages

  Nelson, Sarah J ^a,b   Kurhanewicz, John ^a   Vigneron, Daniel B ^a,b   Larson, Peder E Z ^a   Harzstark, Andrea L ^a   Ferrone, Marcus ^b   Van Criekinge, Mark ^a   Chang, Jose W ^b   Bok, Robert ^a   Park, Ilwoo ^a   Reed, Galen ^a   Carvajal, Lucas ^a   Small, Eric J ^a   Munster, Pamela ^a   Weinberg, Vivian K ^a   Ardenkjaer Larsen, Jan Henrik ^c   Chen, Albert P ^c   Hurd, Ralph E ^c   Odegardstuen, Liv Ingrid ^c   Robb, Fraser J ^d   Tropp, James ^c   Murray, Jonathan A ^c   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GE HEALTHCARE   (United States)

^d USA Instruments Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; BICARBONATE; CARBON 13; LACTIC ACID; LACTIC ACID C 13; PYRUVIC ACID; PYRUVIC ACID C 13; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; FEASIBILITY STUDY; HUMAN; HUMAN TISSUE; HYPERPOLARIZED METABOLIC IMAGING; IMAGING; IN VIVO STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL NOISE RATIO;

AGED; CARBON ISOTOPES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PYRUVIC ACID; SENSITIVITY AND SPECIFICITY;

EID: 84883879044     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006070     Document Type: Review

References (40)

1. R. Siegel, D. Naishadham, A. Jemal, Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012).
2. M. Han, A. W. Partin, S. Piantadosi, J. I. Epstein, P. C. Walsh, Era specific biochemical recurrencefree survival following radical prostatectomy for clinically localized prostate cancer. J. Urol. 166, 416-419 (2001).
3. J. E. McNeal, D. G. Bostwick, R. A. Kindrachuk, E. A. Redwine, F. S. Freiha, T. A. Stamey, Patterns of progression in prostate cancer. Lancet 1, 60-63 (1986).
4. M. R. Cooperberg, P. R. Carroll, L. Klotz, Active surveillance for prostate cancer: Progress and promise. J. Clin. Oncol. 29, 3669-3676 (2011).
5. J. T. Wei, R. L. Dunn, H. M. Sandler, P. W. McLaughlin, J. E. Montie, M. S. Litwin, L. Nyquist, M. G. Sanda, Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J. Clin. Oncol. 20, 557-566 (2002).
6. J. E. Johansson, O. Andrén, S. O. Andersson, P. W. Dickman, L. Holmberg, A. Magnuson, H. O. Adami, Natural history of early, localized prostate cancer. JAMA 291, 2713-2719 (2004).
7. A. Bill-Axelson, L. Holmberg, M. Ruutu, M. Häggman, S. O. Andersson, S. Bratell, A. Spångberg, C. Busch, S. Nordling, H. Garmo, J. Palmgren, H. O. Adami, B. J. Norlén, J. E. Johansson; Scandinavian Prostate Cancer Group Study No. 4, Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 352, 1977-1984 (2005).
8. S. S. Mehta, D. P. Lubeck, N. Sadetsky, D. J. Pasta, P. R. Carroll, Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: Data from CaPSURE. J. Urol. 171, 215-219 (2004).
9. G. J. Kelloff, P. Choyke, D. S. Coffey; Prostate Cancer Imaging Working Group, Challenges in clinical prostate cancer: Role of imaging. AJR Am. J. Roentgenol. 192, 1455-1470 (2009).
10. J. Kurhanewicz, D. B. Vigneron, Advances in MR spectroscopy of the prostate. Magn. Reson. Imaging Clin. N. Am. 16, 697-710 (2008).
11. J. C. Weinreb, J. D. Blume, F. V. Coakley, T. M. Wheeler, J. B. Cormack, C. K. Sotto, H. Cho, A. Kawashima, C. M. Tempany-Afdhal, K. J. Macura, M. Rosen, S. R. Gerst, J. Kurhanewicz, Prostate cancer: Sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-Results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 251, 122-133 (2009).
12. J. M. Beauregard, S. G. Williams, T. R. Degrado, P. Roselt, R. J. Hicks, Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. J. Med. Imaging Radiat. Oncol. 54, 325-332 (2010).
13. J. H. Ardenkjaer-Larsen, B. Fridlund, A. Gram, G. Hansson, L. Hansson, M. H. Lerche, R. Servin, M. Thaning, K. Golman. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc. Natl. Acad. Sci. U.S.A. 100, 10158-10163 (2003).
14. K. Golman, R. in 't Zandt, M. Thaning, Real-time metabolic imaging. Proc. Natl. Acad. Sci. U.S.A. 103, 11270-11275 (2006).
15. 1. Acad. Radiol. 13, 932-942 (2006).
16. A. P. Chen, M. J. Albers, C. H. Cunningham, S. J. Kohler, Y. F. Yen, R. E. Hurd, J. Tropp, R. Bok, J. M. Pauly, S. J. Nelson, J. Kurhanewicz, D. B. Vigneron, Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-Initial experience. Magn. Reson. Med. 58, 1099-1106 (2007).
17. 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate 73, 1171-1181 (2013).
18. 13C lactate, pyruvate, and alanine: Noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 68, 8607-8615 (2008).
19. 13C spectroscopic imaging informs on hypoxiainducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. Cancer Res. 70, 7400-7410 (2010).
20. 13C magnetic resonance imaging and spectroscopy. Nat. Med. 13, 1382-1387 (2007).
21. National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE) v4.0; http://ctep.cancer.gov.
22. 1-pyruvate metabolism in normal rats and TRAMP mice. J. Magn. Reson. 202, 85-92 (2010).
23. J. H. Ardenkjaer-Larsen, A. M. Leach, N. Clarke, J. Urbahn, D. Anderson, T. W. Skloss, Dynamic nuclear polarization polarizer for sterile use intent. NMR Biomed. 24, 927-932 (2011).
24. 13C]pyruvate in vivo using a sub-kelvin, multisample DNP polarizer. Magn. Reson. Imaging 31, 490-496 (2013).
25. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab. 14, 131-142 (2011).
26. 13C MR metabolic imaging. J. Magn. Reson. Imaging 33, 1284-1290 (2011).
27. 13C]pyruvate in the isolated perfused rat lung-An ischemia study. NMR Biomed. 25, 1113-1118 (2012).
28. 13C magnetic resonance spectroscopy. Cancer Res. 70, 1296-1305 (2010).
29. 2]fumarate. Br. J. Cancer 103, 1400-1406 (2010).
30. M. B. Tessem, M. G. Swanson, K. R. Keshari, M. J. Albers, D. Joun, Z. L. Tabatabai, J. P. Simko, K. Shinohara, S. J. Nelson, D. B. Vigneron, I. S. Gribbestad, J. Kurhanewicz, Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn. Reson. Med. 60, 510-516 (2008).
31. 13C studies. Magn. Reson. Med. 65, 610-619 (2012).
32. A. Arunachalam, D. Whitt, K. Fish, R. Giaquinto, J. Piel, R. Watkins, I. Hancu, Accelerated spectroscopic imaging of hyperpolarized C-13 pyruvate using SENSE parallel imaging. NMR Biomed. 22, 867-873 (2009).
33. 13C pyruvate and bicarbonate in the heart. Magn. Reson. Med. 64, 1323-1331 (2010).
34. 13C]pyruvate. J. Magn. Reson. 206, 210-218 (2010).
35. 13C]pyruvate. Am. J. Physiol. Heart Circ. Physiol. 298, H1556-H1564 (2010).
36. M. A. Schroeder, L. E. Cochlin, L. C. Heather, K. Clarke, G. K. Radda, D. J. Tyler, In vivo assessment of pyruvate dehydrogenase flux in the heart using hyperpolarized carbon-13 magnetic resonance. Proc. Natl. Acad. Sci. U.S.A. 105, 12051-12056 (2008).
37. 13C-pyruvate with MR imaging and spectroscopy. Radiology 259, 414-420 (2011).
38. J. Tropp, P. Calderon, D. Vigneron, Systems, methods and apparatus for an endo-rectal receive-only probe, U.S. Patent 7945308 (2011).
39. J. C. Crane, M. P. Olson, S. J. Nelson, SIVIC: An open-source DICOM software framework and plug-in for OsiriX PACS, International Society for Magnetic Resonance in Medicine 18th Scientific Meeting, 2010.
40. 13C]pyruvate. Sci. Transl. Med. 5, 198ra108 (2013.)